EMAIL THIS PAGE TO A FRIEND

Anti-cancer drugs

Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.


PMID 24800886

Abstract

Therapeutic strategies targeting histone deacetylase (HDAC) inhibition have become promising in many human malignancies. Belinostat (PXD101) is a hydroxamate-type HDAC inhibitor tested in phase I and II clinical trials in solid tumors and hematological cancers. However, little is known about the use of belinostat for differentiation therapy against acute myelogenous leukemia. Here, we characterize the antileukemia activity of belinostat as a single drug and in combination with all-trans-retinoic acid (RA) in promyelocytic leukemia HL-60 and NB4 cells. Belinostat exerted dose-dependent growth-inhibitory or proapoptotic effects, promoting cell cycle arrest at the G0/G1 or the S transition. Apoptosis was accompanied by activation of caspase 3, degradation of PARP-1, and cell cycle-dependent changes in the expression of survivin, cyclin E1, and cyclin A2. Belinostat induced a dose-dependent reduction in the expression of EZH2 and SUZ12, HDAC-1, HDAC-2, and histone acetyltransferase PCAF (p300/CBP-associated factor). Belinostat increased acetylation of histone H4, H3 at K9 and H3 at K16 residues in a dose-dependent manner, but did not reduce trimethylation of H3 at K27 at proapoptotic doses. Combined treatment with belinostat and RA dose dependently accelerated and reinforced granulocytic differentiation, accompanied by changes in the expression of CD11b, C/EBPα (CCAAT/enhancer binding protein-α), and C/EBPε. Our results concluded the usefulness of belinostat, as an epigenetic drug, for antileukemia and differentiation therapy.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

E7031
Anti-EZH2 (N-terminal) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB1405776
Anti-EZH2 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
E6906
Anti-EZH2 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
AV38470
Anti-EZH2 antibody produced in rabbit, IgG fraction of antiserum, lyophilized powder
SAB2106436
Anti-EZH2 antibody produced in rabbit, affinity isolated antibody
SAB1410354
Anti-EZH2 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
AV48511
Anti-ME3 antibody produced in rabbit, affinity isolated antibody
HPA038473
Anti-ME3 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
AV39190
Anti-SUZ12 (AB2) antibody produced in rabbit, affinity isolated antibody
HPA057436
Anti-SUZ12 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB3501103
Anti-SUZ12 antibody produced in rabbit, affinity isolated antibody
SAB1408985 Monoclonal Anti-EZH2 antibody produced in mouse, clone 1D11, purified immunoglobulin, buffered aqueous solution
SAB5300013 Monoclonal Anti-SUZ12 antibody produced in mouse, clone 3D10, ascites fluid
SAB5300014
Monoclonal Anti-SUZ12 antibody produced in mouse, clone 2C11, ascites fluid